Equities research analysts predict that Athenex, Inc. (NASDAQ:ATNX) will report earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Athenex’s earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.37). Athenex reported earnings of ($0.28) per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The firm is expected to issue its next quarterly earnings results on Thursday, February 25th.
On average, analysts expect that Athenex will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.55). For the next year, analysts anticipate that the business will post earnings of ($1.32) per share, with EPS estimates ranging from ($1.99) to ($0.99). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Athenex.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.02. The business had revenue of $35.48 million during the quarter, compared to the consensus estimate of $19.50 million. Athenex had a negative return on equity of 66.12% and a negative net margin of 75.45%.
ATNX opened at $10.68 on Monday. Athenex has a one year low of $5.63 and a one year high of $15.73. The company has a fifty day moving average price of $12.02 and a 200-day moving average price of $12.14. The firm has a market capitalization of $996.86 million, a P/E ratio of -7.32 and a beta of 0.92. The company has a debt-to-equity ratio of 0.57, a current ratio of 4.87 and a quick ratio of 4.43.
In related news, CEO Johnson Yiu Nam Lau acquired 5,000 shares of the stock in a transaction dated Friday, November 6th. The shares were acquired at an average price of $11.70 per share, for a total transaction of $58,500.00. Following the completion of the purchase, the chief executive officer now owns 3,150,959 shares in the company, valued at approximately $36,866,220.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders bought 7,000 shares of company stock worth $83,760. 16.30% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. acquired a new position in shares of Athenex in the 3rd quarter valued at approximately $27,000. Bank of Montreal Can bought a new stake in Athenex during the 2nd quarter worth $76,000. Vigilare Wealth Management bought a new position in shares of Athenex in the third quarter valued at approximately $121,000. Virtu Financial LLC bought a new position in shares of Athenex in the third quarter valued at approximately $129,000. Finally, Aperio Group LLC boosted its position in Athenex by 9.5% during the third quarter. Aperio Group LLC now owns 11,284 shares of the company’s stock valued at $136,000 after buying an additional 981 shares during the period. 57.74% of the stock is owned by hedge funds and other institutional investors.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Featured Article: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.